Business Context and Reporting Period
This Form 8-K Current Report was filed by IRADIMED CORPORATION on March 30, 2017. The filing primarily addresses the appointment of a new executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $200,000 per year.
- Annual Bonus: Eligible for up to 30% of base salary, subject to company profitability and individual performance.
- Equity Grant: Restricted Stock Units (RSUs) valued at $550,000 (based on closing stock price the day preceding the Hire Date).
- Vesting Schedule: Four equal annual installments.
Material Changes
The material change reported is the appointment of John McCreery as Chief Operating Officer (COO).
- Start Date: To commence during April 2017 (specific date not yet determined).
- Responsibilities: Primary oversight of regulatory, manufacturing, and engineering departments.
- Background: Mr. McCreery is a tenured professor at North Carolina State University with prior experience as COO at Invivo Research.
Outlook, Risks, and Contingencies
The filing details specific termination and change of control provisions within the employment agreement:
- Termination without Cause/Good Reason: Entitles Mr. McCreery to six months of base salary.
- Change of Control: If a change of control occurs (transfer of >50% ownership) and Mr. McCreery terminates for good reason, the Company must pay an amount equal to his then-current annual salary (minimum $200,000).
- Restrictions: The agreement includes non-solicitation, non-compete, and confidentiality provisions.
Investor Verification Checklist
- Verify the exact "Hire Date" to determine the specific stock price used for the $550,000 RSU grant calculation.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed definitions of "Good Reason" and "Change of Control."
- Confirm the impact of the new COO's appointment on the Company's operational strategy for regulatory and manufacturing departments.
- Check subsequent filings for the actual vesting schedule and any adjustments to the bonus structure based on performance.